secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pulmatrix, Inc. (PULM)
CIK:        0001574235
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001493152-26-008129
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulmatrix: $0 revenue in 2025, net loss $5.2M, plans to license iSPERSE
-----------------------------------------------------------------------

- Revenue $0 in 2025 vs $7.8M in 2024; net loss $5.2M ($1.41/share) vs $9.6M.
- Cash and equivalents $4.1M at Dec 31, 2025, down from $9.5M; cash runway into Q1 2027.
- Plans to license or monetize iSPERSE platform and migraine asset PUR3100.
- Proposed merger with Cullgen pending CSRC approval; 'No Solicitation' clause waived to explore alternatives.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1574235/000149315226008129/0001493152-26-008129-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1574235/000149315226008129/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-008129

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer